2nd Annual Oncology Clinical Development Congress 2013

  • Conference Call
  • Oxford Global Conferences are proud to present the 2nd Annual Oncology Clinical Development Congress 2013 which will be held on the 14th & 15th October 2013, at the Hilton Manchester Deansgate, UK.

    It is estimated that each year 12.7million people are diagnosed with cancer across the globe. Our experts will discuss the latest advances in the development of targeted therapies and explore their translation into clinical trials.

    There is much debate as to whether oncology therapies should increase the quality of life or the lifespan of the patient; join our renowned speakers in identifying appropriate clinical endpoints. On day one hear from industry leaders working at the forefront of oncology co-development. Topics for discussion include mechanisms of cancer drug resistance, strategies to reach critical go/no go decisions and novel imaging technologies.

    On day two our distinguished speakers will explore case studies of global clinical trials, strategies to overcome operational challenges and methods to ensure effective patient recruitment and retention. Our experts will discuss approaches to reduce clinical timelines, cost of adaptive clinical trial designs and methods of methods of appropriate site selection.

    Co-located with our 3rd Annual Oncology Biomarkers Congress, this event, attracting over 150 senior-level decision makers, is a must for anyone working in Oncology Clinical Development.

    Agenda

    In keeping with Oxford Global’s highly successful life sciences series, an expert panel of 20 speakers will present a full conference programme covering the topics outlined below.

    Day 1 – Optimising Clinical Development in Oncology

    • Targeted therapies in clinical development; antibody, vaccines & cell-based therapies
    • Overcoming the mechanisms of cancer drug resistance
    • Co-development of combined oncology therapies
    • Identifying appropriate clinical endpoints
    • Strategies to reach critical go/no-go decisions earlier
    • Novel technologies for imaging in drug development
    • Pharmacovigilance & patient safety
    • Integrating biomarkers in clinical development & trials

    Day 2 – Operational Challenges of Oncology Clinical Trials

    • Establishing the correct trial population; emerging markets, global trials
    • Adaptive clinical trial design
    • Appropriate site selection
    • Regulatory considerations
    • Clinical trial management
    • Patient recruitment and retention strategies
    • Successfully maintaining CRO relationships
    • Effective use of clinical data & eClinical solutions

    Who is speaking

    Our speaker programmes are carefully researched each year to ensure that delegates are exposed to the highest level of expertise. However, delegates not only benefit from the experience of our speakers, but also gain an insight into the experiences of other attendees – Q&A sessions and panel discussions are utilised to enable sharing of knowledge and facilitate idea exchange.

    If you have a cutting edge case study or relevant presentation and would like to join the speaker panel at one of our events, please contact Arti Pau at a.pau@oxfordglobal.co.uk.

    Confirmed 2013 Speakers

    • Amer Alghabben - Director, Merck Serono
    • Philip M Arlen - President & CEO, Precision Biologics
    • Özlem Ataman - Clinical Director, Janssen
    • Laurent Audoly - CSO and Head of R&D, Pieris
    • Annick Bessems - Director, Clinical Program Leader Oncology, Global Clinical Operations, Janssen
    • Robert Clarke - Senior Lecturer, Paterson Institute for Cancer Research, University of Manchester
    • Mayukh Das - Medical Lead, Eli Lilly
    • Janet Flisak - Director, Johnson & Johnson
    • Serban Ghiorghiu - Director, AstraZeneca
    • Christopher Hart - Clinical Information Science Director, AstraZeneca
    • Mike Lau - Director Medical Affairs, GlaxoSmithKline Oncology
    • Grace Macaulay - Senior Drug Safety Physician - Oncology, Mundipharma Research Ltd
    • Aung Myo - Director, Head of Clinical Development, Cancer Immunotherapeutics, Asia and Australia, GlaxoSmithKline Biologicals
    • Yuka Sato Olivo - Associate Director, Clinical Trial Management, Boehringer Ingelheim
    • Alex Phipps - Clinical Pharmacology Head - Oncology, Roche
    • Alison Rees - Country Head Global Monitoring Operations, Novartis Pharmaceuticals UK Limited
    • Robin Wiltshire - Global Medical Affairs Lead, Pfizer

    Who will attend

    The 2nd Annual Oncology Clinical Development Congress is an exclusive event consisting of world-class keynote addresses and panel discussions designed specifically for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions. Delegates typically include VPs, Directors, Managers and Heads of:

    • Clinical Imaging
    • Clinical Outsourcing
    • Clinical Protocol
    • Compliance Management
    • Global Clinical Operations
    • Licensing and Partnerships
    • Oncology Clinical Development
    • Oncology Clinical Research
    • Patient Recruitment
    • Patient Safety
    • Pharmacovigilance
    • Regulatory Affairs
    • Site Management
    • Translational Oncology
    • Trial Design
    • Trial Management
    starting: ending: 15.10.2013 Location: , Category:

    Timeline

    Conference START 15.10.2013 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address Hilton Manchester Deansgate Hotel, Deansgate 303 Category Organiser More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.